For decades, endometriosis has been understood primarily as a hormonal condition — one in which tissue similar to the uterine lining grows outside the uterus, driven largely by estrogen. Hormonal suppression has been the cornerstone of medical treatment ever since. But a landmark new review published in the Journal of Advanced Research is challenging that framework in a profound way, arguing that endometriosis is, at its core, a metabolic disease — and that understanding it as such could finally open the door to treatments that go far beyond hormones.
What Is Endometriosis — And Why Is It So Hard to Treat?
Endometriosis affects an estimated 1 in 10 women of reproductive age worldwide. It causes chronic pelvic pain, painful periods, pain with intercourse, and — for many women — significant difficulty getting pregnant. Despite how common it is, the average time to diagnosis is still 7 to 10 years, and treatment options remain frustratingly limited.
Current treatments — hormonal birth control, GnRH agonists, and surgery — can reduce symptoms, but they don’t cure the disease. Lesions often return after surgery, symptoms frequently come back after stopping hormonal therapy, and none of the available options address the underlying biology of why these cells survive where they shouldn’t.
That’s exactly the gap this new research aims to fill.
The New Finding: Endometriosis Rewires Its Own Energy System
The review synthesized data from cell studies, animal models, human tissue analysis, and cutting-edge laboratory techniques — including single-cell transcriptomics, spatial metabolomics, and lipidomics — to reach a striking conclusion: ectopic endometrial cells (the misplaced cells that define endometriosis) fundamentally reprogram how they produce and use energy in order to survive.
Think of it like this: normal cells follow the body’s energy rules. Endometriosis cells rewrite those rules entirely — adapting their metabolism so they can grow in hostile environments, evade immune detection, and resist the hormonal signals that would otherwise suppress them.
The authors identified three major metabolic shifts that drive the disease:
1. Altered Glucose Metabolism Endometriosis lesions preferentially use a fast, inefficient form of energy production called aerobic glycolysis — the same strategy used by many cancer cells. This allows them to grow rapidly even in low-oxygen environments, like the peritoneal cavity, where these lesions often implant.
2. Disrupted Fat (Lipid) Metabolism The review found significant abnormalities in how endometriosis cells process fatty acids and phospholipids. This altered lipid metabolism appears to support lesion growth, invasion into surrounding tissue, and the creation of a local environment that shields lesions from immune attack.
3. Abnormal Amino Acid Metabolism Changes in how these cells process amino acids — the building blocks of proteins — further fuel their ability to proliferate and evade the immune system, and may help explain why endometriosis has such a profound effect on fertility and implantation.
Critically, the authors argue that this metabolic reprogramming is not just a byproduct of the disease — it is the engine driving disease progression. Hormonal suppression can quiet symptoms, but it doesn’t dismantle this underlying metabolic machinery.
Why This Changes Everything
If endometriosis is fundamentally a metabolic disease, several important things follow:
Hormones alone won’t be enough. Suppressing estrogen addresses one piece of the puzzle but leaves the metabolic adaptations intact — which may explain why lesions so often return after treatment.
New treatment targets are emerging. By mapping these three metabolic pathways, researchers have identified specific molecular targets that could be addressed with existing or newly developed drugs, including some already used in diabetes and oncology.
Diagnosis may become less invasive. Metabolic changes leave measurable footprints in blood, urine, and tissue. Identifying reliable metabolomic biomarkers could eventually enable diagnosis through a blood test rather than surgery — a game-changer for the millions of women waiting years for answers.
Treatment could become personalized. The review suggests that patients may be stratified by their specific metabolic profiles, allowing physicians to match treatment to the underlying biology of each woman’s disease.
What This Means for Our Patients
At El Camino Women’s Medical Group, we understand that endometriosis is one of the most complex and often misunderstood conditions we treat. Our physicians approach every patient as an individual — considering the full picture of pain, fertility goals, cycle patterns, and quality of life.
While metabolically-targeted therapies are not yet available in clinical practice, research like this is moving the field forward quickly. We stay current with emerging evidence so we can offer our patients not only today’s best treatments, but an informed perspective on what’s coming.
If you’ve been struggling with pelvic pain, painful periods, or difficulty conceiving — and feel like your symptoms haven’t been fully explained — we encourage you to come in for a conversation. Endometriosis is underdiagnosed, but it is very much on our radar.
The Bottom Line
A major new review has reframed endometriosis as a disease of cellular metabolism, not just hormones. Misplaced endometrial cells survive and spread by rewiring their own energy systems — becoming resistant to both immune attack and hormonal suppression. This discovery doesn’t change treatment overnight, but it opens a genuinely new frontier in understanding a condition that has frustrated patients and physicians for generations.
We are cautiously optimistic. And we’ll be watching this research closely.
Questions about endometriosis? Our physicians are here to help. Contact our office to schedule a consultation.
El Camino Women’s Medical Group offers the latest Minimally Invasive Solutions for gynecologic problems. Drs. Amy Teng, Erika Balassiano, Pooja Gupta, and Vivian Wan, all members of AAGL (American Association of Gynecologic Laparoscopy), are highly trained and experienced in the field of Minimally Invasive Gynecologic Surgery. Dr. Erika Balassiano has also completed a Minimally Invasive Gynecologic Surgery Fellowship under the supervision of world-renowned Dr. Camran Nezhat. Angel Wong, PA-C, is a physician assistant who sees patients for routine and lower-acuity care.
All of our physicians are El Camino Hospital doctors and operate and deliver at the Mountain View campus.
As part of El Camino Women’s Medical Group’s commitment to comprehensive care for women, we offer in-network mental health services with world-renowned psychiatrist Dr. Rania Awaad and experienced therapist Daniya Ahmed, LMFT. For women seeking to improve their health through a healthier diet, Mariam AlAgha, MS, is an excellent nutritionist with over a decade of success helping women achieve their health goals. Her services are also in network.
Serving Mountain View, Los Altos, Los Altos Hills, Atherton, Palo Alto, Redwood City, Burlingame, Saratoga, Cupertino, Sunnyvale, Los Gatos, Campbell, San Jose, Santa Clara, Silicon Valley, Milpitas, Fremont, South Bay, East Bay, and North Bay.